RecruitingEndometrial Cancer
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Eligible age
18+ yrs
Accepts
Women
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Sponsor: Daiichi Sankyo
Where it's recruiting
Florida
Fort Lauderdale · Miami · Miami Beach
Louisiana
Shreveport
North Carolina
Pinehurst
Ohio
Cincinnati
South Dakota
Sioux Falls
Texas
San Antonio
Source: ClinicalTrials.gov · NCT07022483 · last updated 2026-05-28